{"mainPropery":{"diseaseId":5885,"diseaseName":"Tumefactive multiple sclerosis","hasGardWebPage":true,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/5885/tumefactive-multiple-sclerosis","synonyms":["Diffuse cerebral sclerosis of Schilder","Concentric demyelination","Balo's concentric sclerosis","Marburg variant","Balo disease","Baló concentric sclerosis","Balo's disease","Encephalitis periaxialis concentrica"],"synonyms-with-source":[{"name":"Diffuse cerebral sclerosis of Schilder"},{"name":"Concentric demyelination","source":"OrphaData.Org"},{"name":"Balo's concentric sclerosis","source":""},{"name":"Marburg variant","source":"UpToDate"},{"name":"Balo disease","source":""},{"name":"Baló concentric sclerosis","source":"Orphanet"},{"name":"Balo's disease","source":"National Multiple Sclerosis Society"},{"name":"Encephalitis periaxialis concentrica","source":"National Multiple Sclerosis Society"}],"identifiers":[{"identifierType":"ORPHANET","identifierId":"228165"}]},"diseaseCategories":[{"diseaseTypeId":17,"diseaseTypeName":"Nervous System Diseases","source":"Orphanet"}],"organizations":[{"resourceID":52,"resourceName":"Accelerated Cure Project for Multiple Sclerosis","abbreviation":"","address1":"460 Totten Pond Road","address2":"Suite 140","address3":"","address4":"","address5":"","city":"Waltham ","state":"MA","zip":"02451","country":"United States","phone":"+1-781-487-0008","tty":"","tollFree":"","fax":"+1-781-487-0009","email":"info@acceleratedcure.org","url":"https://www.acceleratedcure.org/","freeText":""},{"resourceID":53,"resourceName":"Multiple Sclerosis Association of America","abbreviation":"","address1":"375 Kings Highway North","address2":"","address3":"","address4":"","address5":"","city":"Cherry Hill","state":"NJ","zip":"08034","country":"United States","phone":"+1-856-488-4500 ","tty":"","tollFree":"1-800-532-7667","fax":"+1-856-661-9797","email":"MSquestions@mymsaa.org  ","url":"https://mymsaa.org/","freeText":""},{"resourceID":54,"resourceName":"Multiple Sclerosis Foundation","abbreviation":"","address1":"6520 North Andrews Avenue","address2":"","address3":"","address4":"","address5":"","city":"Fort. Lauderdale","state":"FL","zip":"33309-2132","country":"United States","phone":"+1-954-776-6805 ","tty":"","tollFree":"1- 888-MSFOCUS (673-6287)","fax":"+1-954-351-0630","email":"support@msfocus.org","url":"https://msfocus.org/","freeText":""},{"resourceID":56,"resourceName":"National Multiple Sclerosis Society","abbreviation":"","address1":"733 Third Avenue, 6th Floor","address2":"","address3":"","address4":"","address5":"","city":"New York","state":"NY","zip":"10017-3288","country":"United States","phone":"+1-212-986-3240","tty":"","tollFree":"1-800-344-4867","fax":"+1-212-986-7981","email":"nat@nmss.org","url":"https://www.nationalmssociety.org/","freeText":""}],"resource descriptions":[{"id":8,"resourceId":11,"resourceName":"PubMed","descriptionText":"<a href='https://www.ncbi.nlm.nih.gov/pubmed/?term=%28tumefactive[All%20Fields]%20AND%20%28%22multiple%20sclerosis%22[MeSH%20Terms]%20OR%20%28%22multiple%22[All%20Fields]%20AND%20%22sclerosis%22[All%20Fields]%29%20OR%20%22multiple%20sclerosis%22[All%20Fields]%29%29%20OR%20%28Balos[All%20Fields]%20AND%20%28%22disease%22[MeSH%20Terms]%20OR%20%22disease%22[All%20Fields]%29%29%20AND%20%28%222006%2F05%2F23%22[PDat]%20%3A%20%222016%2F05%2F19%22[PDat]%29&cmd=DetailsSearch' target='_blank'>PubMed</a> is a searchable database of medical literature and lists journal articles that discuss Tumefactive multiple sclerosis. Click on the link to view a sample search on this topic.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":9,"resourceId":12,"resourceName":"ClinicalTrials.gov","descriptionText":"<a href='http://www.clinicaltrials.gov/ct2/results?cond=%22Balos+concentric+sclerosis%22' target='_blank'>ClinicalTrials.gov</a> lists trials that are related to Tumefactive multiple sclerosis. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies. <br />\r\n<br />\r\n<em><strong>Please note:</strong>&nbsp;Studies listed on the&nbsp;ClinicalTrials.gov&nbsp;website are listed for informational purposes only; being listed does not reflect an endorsement by GARD or the NIH. We strongly recommend that you talk with a trusted healthcare provider before choosing to participate in any clinical study.</em>","resourceClassificationName":"Research","resourceClassificationSectionName":"Clinical Research Resources"},{"id":1527,"resourceId":2159,"resourceName":"National Organization for Rare Disorders","descriptionText":"The <a href='http://rarediseases.org/rare-diseases/balo-disease/' target='_blank'>National Organization for Rare Disorders</a> (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1534,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=228165' target='_blank'>Orphanet</a> is a European reference portal for&nbsp;information on rare diseases and orphan drugs. Access to this database is free of charge.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2117,"resourceId":3331,"resourceName":"MS sociaty Tumefactive multiple sclerosis","descriptionText":"The <a target=\"_blank\" href=\"http://www.nationalmssociety.org/What-is-MS/Related-Conditions/Balo%E2%80%99s-Disease\">National MS Society</a> offers an overview on tumefactive multiple sclerosis, including information on symptoms and treatment.","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/DOID:0060215' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2160,"resourceId":3368,"resourceName":"Patient Access Network Foundation","descriptionText":"<a href='https://panfoundation.org/index.php/en/patients/assistance-programs/multiple-sclerosis' target='_blank'>Patient Access Network Foundation</a> (PAN Foundation) has Assistance Programs for those with health insurance who reside in the United States. The disease fund status can change over time, so you may need to check back if funds are not currently available.&nbsp;","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2162,"resourceId":3371,"resourceName":"The Assistance Fund","descriptionText":"<a href='https://tafcares.org/patients/covered-diseases/' target='_blank'>The Assistance Fund</a> provides various services, including education and financial aid, to help patients with a chronic or serious illness cover the cost of FDA-approved medications. Patients must be U.S citizens or permanent residents.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2163,"resourceId":3372,"resourceName":"Good Days","descriptionText":"<a href='https://www.mygooddays.org/patients/diseases-covered/chronic-iron-overload' target='_blank'>Good Days</a> provides help to patients with life-altering conditions. Assistance includes help with the cost of medications and travel.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"}],"overviewQuestion":{"questionId":10671,"questionText":"What is tumefactive multiple sclerosis?","answerText":"<strong>Tumefactive multiple sclerosis</strong> is characterized by a tumor-like lesion larger than two centimeters and signs and symptoms similar to those of a brain tumor.[11532][11530] It is a rare form of multiple sclerosis (MS). Symptoms of tumefactive MS often differ from other MS cases and may include, headaches, changes in thinking, confusion, speech problems, seizures, and weakness.[11532] The cause of tumefactive MS is not known. It often develops into the <a target=\"_blank\" href=\"http://www.nationalmssociety.org/What-is-MS/Types-of-MS/Relapsing-remitting-MS\">relapsing-remitting form of MS</a>.[11530][11531] In other cases there is only one occurrence of the condition.[11530] In still others the disease process remains less clear. While there is no cure for tumefactive MS, treatments such as <a target=\"_blank\" href=\"https://www.nlm.nih.gov/medlineplus/steroids.html\">corticosteroids</a> are available to decrease disease activity.[11530][11531]","dateModified":"2016-05-18T15:11:00"},"basicQuestions":[{"questionId":10673,"questionText":"How is tumefactive multiple sclerosis treated?","answerText":"To\r\ndate there have been no controlled treatment studies for tumefactive\r\nmultiple sclerosis. As a result, treatment decisions are largely based\r\non a doctor's experience and information from single case reports.[11531] <br />\r\n<br />\r\nIn a small number of cases, people with tumefactive multiple sclerosis\r\nhave minimal to no symptoms. A reasonable approach of care in these\r\ncases is to  monitor without treatment.[11531] <br />\r\n<br />\r\nIn most cases the\r\nsize of the lesion and resulting symptoms prompts treatment with\r\ncorticosteroids. As with other forms of multiple sclerosis,\r\n<a target=\"_blank\" href=\"https://www.nlm.nih.gov/medlineplus/steroids.html\">corticosteroids</a> (for example, intravenous methylprednisolone) should be the first\r\nline of treatment.&nbsp; If corticosteroids are not effective, <a target=\"_blank\" href=\"https://secure.nationalmssociety.org/site/SPageServer/?pagename=HOM_LIB_sourcebook_plasmapheresis\">plasma exchange</a> is tried. Another second line treatment that has been tried\r\nwith some success is <a target=\"_blank\" href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a607038.html\">Rituximab</a>.[11531]","dateModified":"2016-05-19T13:21:00","resourceClassificationName":"Treatment","references":[{"referenceId":11531,"authors":"Hardy TA, Chataway J","articleTitle":"Tumefactive demyelination: an approach to diagnosis and management","bookWebsiteJournalTitle":"Neurol Neurosurg Psychiatry","date":"2013","volume":"84","pages":"1047","url":"","dateAccessed":"2016-05-18T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]}],"references":[],"relatedDiseases":[{"relatedDiseaseId":12052,"relatedDiseaseName":"Demyelinating disease of central nervous system","relation":"Parent","isRare":false,"hasGardPage":false},{"relatedDiseaseId":10255,"relatedDiseaseName":"Multiple sclerosis","relation":"Parent","isRare":false,"hasGardPage":true}],"gardCases":[{"caseId":56637,"abbreviatedInquiry":"My mother has MS similar to balo disease and now is under control with Methylprednisolone treatment but cannot get cured. Just want to check whether any one has experience about this MS and whether Interferon will work. ","caseQuestions":[{"questionId":10673,"questionText":"How is tumefactive multiple sclerosis treated?","answerText":"To\r\ndate there have been no controlled treatment studies for tumefactive\r\nmultiple sclerosis. As a result, treatment decisions are largely based\r\non a doctor's experience and information from single case reports.[11531] <br />\r\n<br />\r\nIn a small number of cases, people with tumefactive multiple sclerosis\r\nhave minimal to no symptoms. A reasonable approach of care in these\r\ncases is to  monitor without treatment.[11531] <br />\r\n<br />\r\nIn most cases the\r\nsize of the lesion and resulting symptoms prompts treatment with\r\ncorticosteroids. As with other forms of multiple sclerosis,\r\n<a target=\"_blank\" href=\"https://www.nlm.nih.gov/medlineplus/steroids.html\">corticosteroids</a> (for example, intravenous methylprednisolone) should be the first\r\nline of treatment.&nbsp; If corticosteroids are not effective, <a target=\"_blank\" href=\"https://secure.nationalmssociety.org/site/SPageServer/?pagename=HOM_LIB_sourcebook_plasmapheresis\">plasma exchange</a> is tried. Another second line treatment that has been tried\r\nwith some success is <a target=\"_blank\" href=\"https://www.nlm.nih.gov/medlineplus/druginfo/meds/a607038.html\">Rituximab</a>.[11531]","dateModified":"2016-05-19T13:21:00","resourceClassificationName":"Treatment","references":[{"referenceId":11531,"authors":"Hardy TA, Chataway J","articleTitle":"Tumefactive demyelination: an approach to diagnosis and management","bookWebsiteJournalTitle":"Neurol Neurosurg Psychiatry","date":"2013","volume":"84","pages":"1047","url":"","dateAccessed":"2016-05-18T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]},{"questionId":10674,"questionText":"Do people with controlled tumefactive multiple sclerosis benefit from disease modifying therapies, such as interferons?","answerText":"Disease\r\nmodifying therapies (for example, interferon-&beta; and glatiramer acetate)\r\nare most arguably appropriate for people with tumefactive multiple\r\nsclerosis <em></em>who meet multiple sclerosis (MS) diagnostic\r\ncriteria, or who have characteristics suggesting that they'll likely\r\nconvert to MS, or those who have particularly severe or disabling\r\ntumefactive multiple sclerosis, or those who continue to experience\r\nsymptoms, or perhaps those who have worsening lesions on imaging\r\ntests. This is because some people with tumefactive multiple sclerosis\r\ndo not experience a second attack, and for those that do, there is often\r\nalready a delay before their second attack (as compared to relapsing-remitting MS\r\npatients).[11531] <br />\r\n<br />\r\nCareful thought is needed  to weigh the risk for adverse drug effects versus the potential benefit of delaying or\r\npreventing a second attack of tumefactive multiple sclerosis.[11531] <br />\r\n<br />\r\nLastly, certain MS drugs, such as Fingolimod, may be contraindicated. Case reports suggest that this drug may actually trigger tumefactive\r\nlesions.[11531] Both\r\nnegative and beneficial responses have been reported with\r\nNatalizumab.[11531]","dateModified":"2016-05-19T13:22:00","references":[{"referenceId":11531,"authors":"Hardy TA, Chataway J","articleTitle":"Tumefactive demyelination: an approach to diagnosis and management","bookWebsiteJournalTitle":"Neurol Neurosurg Psychiatry","date":"2013","volume":"84","pages":"1047","url":"","dateAccessed":"2016-05-18T00:00:00","authors2":"","placeOfPublication":"","publisher":""}]}]}],"news":[{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[],"EncodedName":"Tumefactive_multiple_sclerosis"}